Clinical Trial Update: Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating finite androgen ablation with or without abiraterone acetate and prednisone in recurrent prostate cancer. The study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• PREDNISONE (Prednisone)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING